Digoxin

Last updated
Digoxin
Digoxin.svg
Digon ball-and-stick.png
Clinical data
Pronunciation /dɪˈdʒɒksɪn/ [1] [2]
Trade names Lanoxin, others
AHFS/Drugs.com Monograph
MedlinePlus a682301
License data
Pregnancy
category
Routes of
administration 		By mouth, intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability 60 to 80% (by mouth)
Protein binding 25%
Metabolism Liver (16%)
Elimination half-life 36 to 48 hours
(normal kidney function)
3.5 to 5 days
(impaired kidney function)
Excretion Kidney
Identifiers
  • 3β-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12β,14-dihydroxy-5β-card-20(22)-enolide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.040.047 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C41H64O14
Molar mass 780.949 g·mol−1
3D model (JSmol)
Melting point 249.3 °C (480.7 °F)
Solubility in water 0.0648 mg/mL (20 °C)
  • O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]7[C@H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C6
  • InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1 Yes check.svgY
  • Key:LTMHDMANZUZIPE-PUGKRICDSA-N Yes check.svgY
   (verify)

Digoxin (better known as Digitalis), sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions. [4] Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. [4] Digoxin is one of the oldest medications used in the field of cardiology. It works by increasing myocardial contractility, increasing stroke volume and blood pressure, reducing heart rate, and somewhat extending the time frame of the contraction. [5] Digoxin is taken by mouth or by injection into a vein. [4] Digoxin has a half life of approximately 36 hours given at average doses in patients with normal renal function. It is excreted mostly unchanged in the urine.

Contents

Common side effects include breast enlargement with other side effects generally due to an excessive dose. [4] [6] These side effects may include loss of appetite, nausea, trouble seeing, confusion, and an irregular heartbeat. [6] Greater care is required in older people and those with poor kidney function. [6] It is unclear whether use during pregnancy is safe. [3]

Digoxin is in the cardiac glycoside family of medications. [4] It was first isolated in 1930 from the foxglove plant, Digitalis lanata . [7] [8] It is on the World Health Organization's List of Essential Medicines. [9] In 2021, it was the 241st most commonly prescribed medication in the United States, with more than 1 million prescriptions. [10] [11]

Medical uses

Irregular heartbeat

The most common indications for digoxin are atrial fibrillation and atrial flutter with rapid ventricular response, [12] [13] especially in older or less active patients, [14] though beta blockers and/or calcium channel blockers may be preferred in some patients, such as younger more active ones, or those without heart failure or hemodynamic instability. [15]

Early observational studies showed an increased risk of death in patients taking digoxin, despite an attempt to allow for other risk factors for death (so-called propensity score matching). [16] [17] However, systematic reviews focusing on randomised controlled trials of digoxin (which ensured similarity between patients on digoxin, and those not on it) showed no difference in mortality. [18] [19] Evidence suggested the increased mortality in patients taking digoxin was due to their having worse heart disease than those not taking it. [20] Cardiac arrhythmias may also occur when patients are prescribed digoxin alongside thiazides and loop diuretics. [21]

Heart failure

Digitalis (i.e. extracts, including digoxin, from the plant genus Digitalis) was the first drug used to treat dropsy (swollen ankles—a symptom of heart failure) following its discovery by William Withering. [22] Alongside diuretics, it was the mainstay of treatment for heart failure for over a century. Since the introduction of other drugs with better outcomes and fewer adverse effects, it is generally now only used where heart failure is associated with atrial fibrillation and or a rapid ventricular rate. [23] In certain circumstances it may be used under specialist guidance in addition to, or instead of, the recommended first-line treatments of ACE inhibitor, beta blocker, mineralocorticoid antagonist, and SGLT-2 inhibitor, where they are not effective or not tolerated. [24] [23]

Abortion

Digoxin is also used intrafetally or amniotically during abortions in the late second trimester and third trimester of pregnancy. It typically causes fetal demise (measured by cessation of cardiac activity) within hours of administration. [25]

Side effects

The occurrence of adverse drug reactions is common, owing to its narrow therapeutic index (the margin between effectiveness and toxicity). Gynaecomastia (enlargement of breast tissue) is mentioned in many textbooks as a side effect, thought to be due to the estrogen-like steroid moiety of the digoxin molecule, [26] but when systematically sought, the evidence for this is equivocal as of 2005. [27] The combination of increased (atrial) arrhythmogenesis and inhibited atrioventricular (AV) conduction (for example paroxysmal atrial tachycardia with AV block – so-called "PAT with block") is said to be pathognomonic (that is, diagnostic) of digoxin toxicity. [28]

Digoxin can lead to cardiac arrhythmias when given with thiazides and loop diuretics. This is because co-administration of Digoxin with drugs such as thiazides and loop diuretics which can cause hypokalemia, low serum levels of potassium in the blood. This exacerbates the potential for cardiac arrythmias because the low levels of potassium reduces the amount of K+ at the ATPase pump and increase calcium levels too much which leads to these arrythmias. [29] It can also cause visual disturbances as well as dizziness or fainting.

Several other drugs associated with ADRs in concommitant use include verapamil, amiodarone, quinidine, tetracycline, and erythromycin.

Overdose

In overdose, the usual supportive measures are needed. If arrhythmias prove troublesome, or malignant hyperkalemia occurs (inexorably rising potassium level due to paralysis of the cell membrane-bound, ATPase-dependent Na/K pumps), the specific antidote is antidigoxin (antibody fragments against digoxin, trade names Digibind and Digifab). [30] The mechanism of action for drugs such as Digibind and Digifab, used when adverse events occur with the use of digoxin, is that the FAB regions on the antibodies created against digoxin expedite the excretion of the drug into urine. Therefore, the amount of digoxin in the body decreases quickly as it gets excreted rapidly.

Pharmacology

Pharmacodynamics

Signal-averaged ECG from a person taking digoxin, explaining ST depressions in mainly precordial leads V4 and V5 Signal-averaged ECG with digoxin.png
Signal-averaged ECG from a person taking digoxin, explaining ST depressions in mainly precordial leads V4 and V5

Digoxin's primary mechanism of action involves inhibition of the sodium potassium adenosine triphosphatase (Na+/K+ ATPase), mainly in the myocardium. [5] This inhibition causes an increase in intracellular sodium levels, resulting in decreased activity of the sodium-calcium exchanger, which normally imports three extracellular sodium ions into the cell and transports one intracellular calcium ion out of the cell. The reversal of this exchanger, triggered by the increase in intracellular sodium, results in an increase in the intracellular calcium concentration that is available to the contractile proteins. The increased calcium concentrations lead to the binding of more calcium to troponin C, which results in increased inotropy. Increased intracellular calcium lengthens phase 4 and phase 0 of the cardiac action potential, which leads to a decrease in heart rate. [31] Increased amounts of Ca2+ also leads to increased storage of calcium in the sarcoplasmic reticulum, causing a corresponding increase in the release of calcium during each action potential. This leads to increased contractility (the force of contraction) of the heart without increasing heart energy expenditure.[ citation needed ]

The inhibition of the sodium pump may also improve baroreceptor sensitivity in heart failure and may explain some of the neurohormonal effects of digoxin. [32]

Digoxin also has important parasympathetic effects, particularly on the atrioventricular node. [33] While it does increase the magnitude of myocardial contractility, the duration of the contraction is only slightly increased. Its use as an antiarrhythmic drug, then, comes from its direct and indirect parasympathetic stimulating properties. Vagus nerve stimulation slows down conduction at the AV node by increasing the refractory period of cardiac myocytes. The slowed AV node gives the ventricles more time to fill before contracting. This negative chronotropic effect is synergistic with the direct effect on cardiac pacemaker cells. The arrhythmia itself is not affected, but the pumping function of the heart improves, owing to improved filling.

Overall, the heart rate is decreased while stroke volume is increased, resulting in a net increase in blood pressure, leading to increased tissue perfusion. This causes the myocardium to work more efficiently, with optimized hemodynamics and an improved ventricular function curve.

Other electrical effects include a brief initial increase in action potential, followed by a decrease as the K+ conductance increases due to increased intracellular amounts of Ca2+ ions. The refractory period of the atria and ventricles is decreased, while it increases in the sinoatrial and AV nodes. A less negative resting membrane potential is made, leading to increased irritability.

The conduction velocity increases in the atria, but decreases in the AV node. The effect upon Purkinje fibers and ventricles is negligible. Automaticity is also increased in the atria, AV node, Purkinje fibers, and ventricles. [34]

ECG changes seen in people taking digoxin include increased PR interval (due to decreased AV conduction) and a shortened QT interval. Also, the T wave may be inverted and accompanied by ST depression. It may cause AV junctional rhythm and ectopic beats (bigeminy) resulting in ventricular tachycardia and fibrillation.

Digoxin is also an M2 receptor muscarinic agonist. [35]

Pharmacokinetics

Digoxin is usually given orally, but can also be given by IV injection in urgent situations (the IV injection should be slow, and heart rhythm should be monitored). While IV therapy may be better tolerated (less nausea), digoxin has a very long distribution half-life into the cardiac tissue, which will delay its onset of action by a number of hours. The half-life is about 36 hours for patients with normal renal function, digoxin is given once daily, usually in 125 μg or 250 μg doses.[ citation needed ]

Digoxin elimination is mainly by renal excretion and involves P-glycoprotein, which leads to significant clinical interactions with P-glycoprotein inhibitor drugs. Examples commonly used in patients with heart problems include spironolactone, verapamil and amiodarone. In patients with decreased kidney function the half-life is considerably longer, along with decrease in Vd (volume of distribution), calling for a reduction in dose or a switch to a different glycoside, such as digitoxin (not available in the United States), which has a much longer elimination half-life of around seven days and is eliminated by the liver.[ citation needed ]

Effective plasma levels vary depending on the medical indication. For congestive heart failure, levels between 0.5 and 1.0 ng/mL are recommended. [36] This recommendation is based on post hoc analysis of prospective trials, suggesting higher levels may be associated with increased mortality rates. For heart rate control (atrial fibrillation), plasma levels are less defined and are generally titrated to a goal heart rate. Typically, digoxin levels are considered therapeutic for heart rate control between 0.5 and 2.0 ng/mL (or 0.6 and 2.6 nmol/L). [37] In suspected toxicity or ineffectiveness, digoxin levels should be monitored. Plasma potassium levels also need to be closely controlled (see side effects, below).

Quinidine, verapamil, and amiodarone increase plasma levels of digoxin (by displacing tissue binding sites and depressing renal digoxin clearance), so plasma digoxin must be monitored carefully when coadministered. [ citation needed ]

A study which looked to see if digoxin affected men and women differently found that digoxin did not reduce deaths overall, but did result in less hospitalization. Women who took digoxin died "more frequently" (33%) than women who took placebo (29%). Digoxin increased the risk of death in women by 23%. There was no difference in the death rate for men in the study. [38]

Digoxin is also used as a standard control substance to test for P-glycoprotein inhibition. [39]

Digoxin appears to be a peripherally selective drug due to limited brain uptake caused by binding to P-glycoprotein. [40] [41]

Pharmacomicrobiomics

The bacteria Eggerthella lenta has been linked to a decrease in the toxicity of Digoxin. [42] These effects have been studied through comparisons of North Americans and Southern Indians, in which a reduced digoxin metabolite profile correlates with E. lenta abundance. [43] Further studies have also revealed an increase in digoxin toxicity when used alongside erythromycin or tetracycline, the researches attributed this to the decrease in the E. lenta population. [44]

History

Derivatives of plants of the genus Digitalis have a long history of medical use. Nicholas Culpeper referred to various medical uses for Foxglove in his 1652 publication The English physician. [45] William Withering is credited with the first published description of the systematic use of Digitalis derivatives in his 1785 book An Account of the Foxglove and some of its Medical Uses With Practical Remarks on Dropsy and Other Diseases. [46] Its use was somewhat sporadic until Sir James Mackenzie identified the phenomenon of atrial fibrillation, and the actions of digitalis on this. [47] Its effects were first explained by Arthur Robertson Cushny. [48] The name is a portmanteau, derived from Digitalis lanata and toxin. [49]

In 1930, Digoxin was first isolated by Dr. Sydney Smith from the foxglove plant, Digitalis lanata . [7] [8] [50] Initially, the digoxin was purified by dissolving the dried plant material in acetone and boiling the solution in chloroform. The solution was then reacted with acetic acid and small amount of ferric chloride and sulfuric acid (Keller reaction). Digoxin was distinguishable from other glucosides by the olive-green colored solution produced from this reaction, completely free of red. [50]

Society and culture

Charles Cullen admitted in 2003 to killing as many as 40 hospital patients with overdoses of heart medication—usually digoxin—at hospitals in New Jersey and Pennsylvania over his 19-year career as a nurse. On March 10, 2006, he was sentenced to 18 consecutive life sentences and is not eligible for parole. [51]

On April 25, 2008, the U.S. Food and Drug Administration (FDA) issued a press release [52] alerting the public to a Class I recall of Digitek, a brand of digoxin produced by Mylan. [53] Some tablets had been released at double thickness and therefore double strength, causing some patients to experience digoxin toxicity. A class-action lawsuit against the Icelandic generic drug maker Actavis was announced two weeks later. [54]

On March 31, 2009, the FDA announced another generic digoxin pill recall by posting this company press release on the agency's web site: "Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability". A March 31 press release from Caraco, a generic pharmaceutical company, stated:

[All] tablets of Caraco brand Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011, are being voluntarily recalled to the consumer level. The tablets are being recalled because they may differ in size and therefore could have more or less of the active ingredient, digoxin.[ citation needed ]

A 2008 study suggested digoxin has beneficial effects not only for the heart, but also in reducing the risk of certain kinds of cancer. [55] However, comments on this study suggested that digoxin is not effective at reducing cancer risk at therapeutic concentrations of the drug, [56] so the results need further investigation. [57]

Brand names

Digoxin preparations are marketed under the brand names Cardigox; Cardiogoxin; Cardioxin; Cardoxin; Coragoxine; Digacin; Digicor; Digitek; Digomal; Digon; Digosin; Digoxine Navtivelle; Digoxina-Sandoz; Digoxin-Sandoz; Digoxin-Zori; Dilanacin; Eudigox; Fargoxin; Grexin; Lanacordin; Lanacrist; Lanicor; Lanikor; Lanorale; Lanoxicaps; Lanoxin; Lanoxin PG; Lenoxicaps; Lenoxin; Lifusin; Mapluxin; Natigoxin; Novodigal; Purgoxin; Sigmaxin; Sigmaxin-PG; Toloxin. [58] [59]

Digoxin and cancer

Cardiac glycosides, particularly digoxin, have been conventionally used for treatment of common cardiac problems, mainly heart failure and cardiac arrhythmias. The interaction of digoxin and cancer has also been studied. Despite existence of numerous preclinical studies that investigated the anticancer effects of digoxin, there are no solid and conclusive results so far.

Several studies have suggested that digoxin may have anticancer properties, [60] others not. [61]

Digoxin, as a cardiac glycoside, has a chemical structure basically similar to that of estradiol. Digoxin has the ability to bind oestrogen receptors, and therefore it has been proposed that it might increase the risk of oestrogen-sensitive breast and uterine cancers. [62] A large Danish study found a complicated picture, with slightly increased risk of breast cancer amongst women taking digoxin, but better prognostic features. [63] The Nurses' Health Study found a similar slight increase of risk. [64]

Digoxin inhibits the proliferation of many cancerous cell lines in vitro, [65] [66] but its relevance to cancer in vivo remains unclear.

Related Research Articles

<span class="mw-page-title-main">Cardiac glycoside</span> Class of organic compounds

Cardiac glycosides are a class of organic compounds that increase the output force of the heart and decrease its rate of contractions by inhibiting the cellular sodium-potassium ATPase pump. Their beneficial medical uses are as treatments for congestive heart failure and cardiac arrhythmias; however, their relative toxicity prevents them from being widely used. Most commonly found as secondary metabolites in several plants such as foxglove plants, these compounds nevertheless have a diverse range of biochemical effects regarding cardiac cell function and have also been suggested for use in cancer treatment.

<i>Digitalis</i> Genus of flowering plants in the family Plantaginaceae

Digitalis is a genus of about 20 species of herbaceous perennial plants, shrubs, and biennials, commonly called foxgloves.

<span class="mw-page-title-main">Digitoxin</span> Chemical compound

Digitoxin is a cardiac glycoside used for the treatment of heart failure and certain kinds of heart arrhythmia. It is a phytosteroid and is similar in structure and effects to digoxin, though the effects are longer-lasting. Unlike digoxin, which is eliminated from the body via the kidneys, it is eliminated via the liver, and so can be used in patients with poor or erratic kidney function. While several controlled trials have shown digoxin to be effective in a proportion of patients treated for heart failure, the evidence base for digitoxin is not as strong, although it is presumed to be similarly effective.

<span class="mw-page-title-main">Sinus node dysfunction</span> Medical condition

Sinus node dysfunction (SND), also known as sick sinus syndrome (SSS), is a group of abnormal heart rhythms (arrhythmias) usually caused by a malfunction of the sinus node, the heart's primary pacemaker. Tachycardia-bradycardia syndrome is a variant of sick sinus syndrome in which the arrhythmia alternates between fast and slow heart rates.

<span class="mw-page-title-main">Quinidine</span> Antiarrythmic medication

Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances. It is a diastereomer of antimalarial agent quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. As of 2019, its IV formulation is no longer being manufactured for use in the United States.

<span class="mw-page-title-main">Amiodarone</span> Antiarrhythmic medication used for various types of irregular heartbeats

Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias. This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia. Evidence in cardiac arrest, however, is poor. It can be given by mouth, intravenously, or intraosseously. When used by mouth, it can take a few weeks for effects to begin.

<span class="mw-page-title-main">Flecainide</span> Antiarrhythmic medication

Flecainide is a medication used to prevent and treat abnormally fast heart rates. This includes ventricular and supraventricular tachycardias. Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. Its use does not decrease a person's risk of death. It is taken by mouth or injection into a vein.

<span class="mw-page-title-main">Sotalol</span> Medication

Sotalol, sold under the brand name Betapace among others, is a medication used to treat and prevent abnormal heart rhythms. Evidence does not support a decreased risk of death with long term use. It is taken by mouth or given by injection into a vein.

<span class="mw-page-title-main">Cerberin</span> Chemical compound

Cerberin is a type of cardiac glycoside, a steroidal class found in the seeds of the dicotyledonous angiosperm genus Cerbera; including the suicide tree and the sea mango. This class includes digitalis-like agents, channel-blockers that as a group have found historic uses as cardiac treatments, but which at higher doses are extremely toxic; in the case of cerberin, consumption of the C. odollam results in poisoning with presenting nausea, vomiting, and abdominal pain, often leading to death. The natural product has been structurally characterized, its toxicity is clear—it is often used as an intentional human poison in third-world countries, and accidental poisonings with fatalities have resulted from individuals even indirectly consuming the agent—but its potentially therapeutic pharmacologic properties are very poorly described.

<span class="mw-page-title-main">Milrinone</span> Chemical compound

Milrinone, sold under the brand name Primacor, is a pulmonary vasodilator used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.

<span class="mw-page-title-main">Levosimendan</span> Pharmaceutical drug

Levosimendan (INN) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax. Overall the drug has a two fold mechanism of action. It leads to greater inotrophy by increasing the calcium sensitivity as it binds to troponin and this results in a greater positive inotrophic force. Secondly, the drug is able to open ATP sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased preload and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved for use in the United States yet.

<i>Digitalis lanata</i> Species of flowering plant in the plantain family Plantaginaceae

Digitalis lanata, vernacularly often called woolly foxglove or Grecian foxglove, is a species of foxglove, a flowering plant in the plantain family Plantaginaceae. It gets its name due to the woolly indumentum of the leaves. D. lanata, like other foxglove species, is toxic in all parts of the plant. Symptoms of digitalis poisoning include nausea, vomiting, severe headache, dilated pupils, problems with eyesight, and convulsions at the worst level of toxicity. The plant is also harmful to other animals.

<span class="mw-page-title-main">Dronedarone</span> Drug

Dronedarone, sold under the brand name Multaq, is a class III antiarrhythmic medication developed by Sanofi-Aventis. It was approved by the FDA on July 2, 2009. Besides being indicated in arrhythmias, it was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths, in patients with moderate to severe CHF.

<span class="mw-page-title-main">Lanatoside C</span> Chemical compound

Lanatoside C is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia. Lanatoside C can be used orally or by the intravenous route. It is marketed in a number of countries and is also available in generic form. Its main indications are rapid response atrial fibrilation and paroxysmal supraventricular tachycardia, two common types of arrhythmia.

<span class="mw-page-title-main">Pilsicainide</span> Chemical compound

Pilsicainide (INN) is an antiarrhythmic agent. It is marketed in Japan as サンリズム (Sunrythm). It was developed by Suntory Holdings Limited and first released in 1991. The JAN applies to the hydrochloride salt, pilsicainide hydrochloride.

<span class="mw-page-title-main">Landiolol</span> Chemical compound

Landiolol (INN) is an ultra short-acting, β1-superselective intravenous adrenergic antagonist, which decreases the heart rate effectively with less negative effect on blood pressure or myocardial contractility. In comparison to other beta blockers, landiolol has the shortest elimination half-life, ultra-rapid onset of effect, and predictable effectiveness with inactive metabolites. The pure S-enantiomer structure of landiolol is believed to develop less hypotensive side effects in comparison to other β-blockers. This has a positive impact on the treatment of patients when reduction of heart rate without decrease in arterial blood pressure is desired. Landiolol was developed by modifying the chemical structure of esmolol to produce a compound with a higher rate of cardioselectivity and a greater potency without increasing its duration of action. It is sold as landiolol hydrochloride. Based on its positive benefit risk profile, landiolol has been granted the marketing authorization and introduced to the European markets under the brand names Rapibloc, Raploc, Runrapiq, Landibloc mid 2016. Landiolol is available in Japan under the brand names Onoact (50 mg) and Corbeta.

<span class="mw-page-title-main">Digoxin toxicity</span> Medical condition

Digoxin toxicity, also known as digoxin poisoning, is a type of poisoning that occurs in people who take too much of the medication digoxin or eat plants such as foxglove that contain a similar substance. Symptoms are typically vague. They may include vomiting, loss of appetite, confusion, blurred vision, changes in color perception, and decreased energy. Potential complications include an irregular heartbeat, which can be either too fast or too slow.

<span class="mw-page-title-main">Atrial fibrillation</span> Irregular beating of the atria of the heart

Atrial fibrillation is an abnormal heart rhythm (arrhythmia) characterized by rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating, which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF.

<span class="mw-page-title-main">Convallatoxin</span> Chemical compound

Convallatoxin is a glycoside extracted from Convallaria majalis.

<span class="mw-page-title-main">Budiodarone</span> Chemical compound

Budiodarone (ATI-2042) is an antiarrhythmic agent and chemical analog of amiodarone that is currently being studied in clinical trials. Amiodarone is considered the most effective antiarrhythmic drug available, but its adverse side effects, including hepatic, pulmonary and thyroid toxicity as well as multiple drug interactions, are discouraging its use. Budiodarone only differs in structure from amiodarone through the presence of a sec-butyl acetate side chain at position 2 of the benzofuran moiety. This side chain allows for budiodarone to have a shorter half-life in the body than amiodarone which allows it to have a faster onset of action and metabolism while still maintaining similar electrophysiological activity. The faster metabolism of budiodarone allows for fewer adverse side effects than amiodarone principally due to decreased levels of toxicity in the body.

References

  1. ↑ "Digoxin". Digoxin | Definition of Digoxin by Lexico. Lexico. Archived from the original on 27 October 2019. Retrieved 28 October 2019.
  2. ↑ "digoxin". WordReference. Retrieved 28 October 2019.
  3. 1 2 "Digoxin Use During Pregnancy". Drugs.com. Archived from the original on 21 December 2016. Retrieved 14 December 2016.
  4. 1 2 3 4 5 "Digoxin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  5. 1 2 Patocka J, Nepovimova E, Wu W, Kuca K (October 2020). "Digoxin: Pharmacology and toxicology-A review". Environmental Toxicology and Pharmacology. 79: 103400. doi:10.1016/j.etap.2020.103400. PMID   32464466. S2CID   218950180.
  6. 1 2 3 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 270. hdl: 10665/44053 . ISBN   9789241547659.
  7. 1 2 Cartwright AC (2016). The British Pharmacopoeia, 1864 to 2014: Medicines, International Standards and the State. Routledge. p. 183. ISBN   9781317039792. Archived from the original on 2017-09-08.
  8. 1 2 Hollman A (April 1996). "Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata". BMJ. 312 (7035): 912. doi:10.1136/bmj.312.7035.912. PMC   2350584 . PMID   8611904.
  9. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  10. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  11. ↑ "Digoxin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  12. ↑ Sticherling C, Oral H, Horrocks J, Chough SP, Baker RL, Kim MH, et al. (November 2000). "Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness". Circulation. 102 (20): 2503–8. doi: 10.1161/01.CIR.102.20.2503 . PMID   11076824. S2CID   127927.
  13. ↑ Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H (October 2007). "Digoxin and mortality in atrial fibrillation: a prospective cohort study". European Journal of Clinical Pharmacology. 63 (10): 959–71. doi:10.1007/s00228-007-0346-9. PMID   17684738. S2CID   30951337.
  14. ↑ Kumar and clark's clinical medicine (9th ed.). Edinburgh London New York Oxford Philadelphia St Louis Sydney Toronto: Elsevier. 2017. p. 972. ISBN   9780702066009.
  15. ↑ January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. (July 2019). "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons". Circulation. 140 (2): e125–e151. doi: 10.1161/CIR.0000000000000665 . PMID   30686041. S2CID   59304609.
  16. ↑ Ouyang AJ, LvYN, Zhong HL, Wen JH, Wei XH, Peng HW, et al. (April 2015). "Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation". The American Journal of Cardiology. 115 (7): 901–906. doi: 10.1016/j.amjcard.2015.01.013 . PMID   25660972.
  17. ↑ Vamos M, Erath JW, Hohnloser SH (July 2015). "Digoxin-associated mortality: a systematic review and meta-analysis of the literature". European Heart Journal. 36 (28): 1831–1838. doi: 10.1093/eurheartj/ehv143 . PMID   25939649.
  18. ↑ Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC (2018-03-08). "Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials". PLOS ONE. 13 (3): e0193924. Bibcode:2018PLoSO..1393924S. doi: 10.1371/journal.pone.0193924 . PMC   5843263 . PMID   29518134.
  19. ↑ Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. (August 2015). "Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data". BMJ. 351: h4451. doi:10.1136/bmj.h4451. PMC   4553205 . PMID   26321114.
  20. ↑ Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. (August 2015). "Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data". BMJ. 351: h4451. doi:10.1136/bmj.h4451. PMC   4553205 . PMID   26321114.
  21. ↑ Kumar and Clark's clinical medicine (9th ed.). Edinburgh London New York Oxford Philadelphia St Louis Sydney Toronto: Elsevier. 2017. p. 24. ISBN   9780702066009.
  22. ↑ Withering W (1785). An Account of the Foxglove and some of its Medical Uses. Birmingham, England: M. Swinney.
  23. 1 2 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. (September 2021). "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure". European Heart Journal. European Society of Cardiology. 42 (36): 3599–3726. doi: 10.1093/eurheartj/ehab368 . PMID   34447992.
  24. ↑ Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. (November 2017). "2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure". The Canadian Journal of Cardiology. 33 (11): 1342–1433. doi: 10.1016/j.cjca.2017.08.022 . PMID   29111106.
  25. ↑ Paul M, Lichtenberg S, Borgatta L, Grimes DA, Stubblefield PG, Creinin MD (2011-08-24). Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care. John Wiley & Sons. ISBN   9781444358476. Archived from the original on 2017-09-08.
  26. ↑ Moscovitz T, Aldrighi JM, Abrahanshon PA, Zorn TM, Logullo AF, Gebara OC, et al. (April 2005). "Repercussions of digoxin, digitoxin and estradiol on the endometrial histomorphometry of oophorectomized mice". Gynecological Endocrinology. 20 (4): 213–20. doi:10.1080/09513590400021219. PMID   16019364. S2CID   22855158.
  27. ↑ Thompson DF, Carter JR (1993). "Drug-induced gynecomastia". Pharmacotherapy. 13 (1): 37–45. doi:10.1002/j.1875-9114.1993.tb02688.x. PMID   8094898. S2CID   30322620.
  28. ↑ Doering W, König E, Sturm W (March 1977). "[Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)]" [Digitalis intoxication: specificity and significance of cardiac and extracardiac symptoms. Part I: Patients with Digitalis -induced arrhythmias ]. Zeitschrift für Kardiologie (in German). 66 (3): 121–8. PMID   857452.
  29. ↑ Ritter J, Lewis L, Mant T, Ferro A (2008). A Textbook of Clinical Pharmacology and Therapeutics (5th ed.). London: Hodder Arnold. p. 75. ISBN   978-0-340-90046-8.
  30. ↑ Flanagan RJ, Jones AL (2004). "Fab antibody fragments: some applications in clinical toxicology". Drug Safety. 27 (14): 1115–33. doi:10.2165/00002018-200427140-00004. PMID   15554746. S2CID   40869324. Archived from the original on January 16, 2013. Retrieved July 16, 2007.
  31. ↑ Tripathi, K. D., ed. (2008-12-01). Essentials of Medical Pharmacology (6th ed.). New Delhi: Jaypee Publications. p. 498. ISBN   978-81-8448-085-6.
  32. ↑ Wang W, Chen JS, Zucker IH (June 1990). "Carotid sinus baroreceptor sensitivity in experimental heart failure". Circulation. 81 (6): 1959–66. doi:10.1161/01.cir.81.6.1959. PMID   2344687.
  33. ↑ Gheorghiade M, Adams KF, Colucci WS (June 2004). "Digoxin in the management of cardiovascular disorders". Circulation. 109 (24): 2959–64. doi: 10.1161/01.cir.0000132482.95686.87 . PMID   15210613. S2CID   33752611.
  34. ↑ Cunningham L (2018). Cardiology Secrets. Elsevier. pp. 241–252. ISBN   978-0-323-47870-0. Archived from the original on 2021-04-20. Retrieved 2021-03-28.
  35. ↑ King GS, Goyal A, Grigorova Y, Hashmi MF (2023). "Antiarrhythmic Medications". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   29493947 . Retrieved 7 May 2023.
  36. ↑ Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. (September 2005). "ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society". Circulation. 112 (12): e154-235. doi: 10.1161/CIRCULATIONAHA.105.167586 . PMID   16160202.
  37. ↑ Dart RC (2004). "Digoxin and Therapeutic Cardiac Glycosides". Medical Toxicology. Lippincott Williams & Wilkins. p. 700. ISBN   978-0-7817-2845-4. Archived from the original on 2017-09-08. Retrieved 2016-12-15.()
  38. ↑ Rathore SS, Wang Y, Krumholz HM (October 2002). "Sex-based differences in the effect of digoxin for the treatment of heart failure". The New England Journal of Medicine. 347 (18): 1403–11. doi: 10.1056/NEJMoa021266 . PMID   12409542.
  39. ↑ Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. (March 2010). "Membrane transporters in drug development". Nature Reviews. Drug Discovery. 9 (3): 215–236. doi:10.1038/nrd3028. PMC   3326076 . PMID   20190787.
  40. ↑ Fromm MF (February 2000). "P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs". Int J Clin Pharmacol Ther. 38 (2): 69–74. doi:10.5414/cpp38069. PMID   10706193.
  41. ↑ Schinkel AH (April 1999). "P-Glycoprotein, a gatekeeper in the blood-brain barrier". Adv Drug Deliv Rev. 36 (2–3): 179–194. doi:10.1016/s0169-409x(98)00085-4. PMID   10837715.
  42. ↑ "PharmacoMicrobiomics". pharmacomicrobiomics.com. Archived from the original on 2021-06-02. Retrieved 2020-08-13.
  43. ↑ Mathan VI, Wiederman J, Dobkin JF, Lindenbaum J (July 1989). "Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora". Gut. 30 (7): 971–7. doi:10.1136/gut.30.7.971. PMC   1434295 . PMID   2759492.
  44. ↑ Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR (October 1981). "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy". The New England Journal of Medicine. 305 (14): 789–94. doi:10.1056/NEJM198110013051403. PMID   7266632.
  45. ↑ Culpeper N (1652). The English Physician, Etc (1st ed.). London: William Bentley. pp. 97–98. Retrieved 22 January 2023.
  46. ↑ Withering W (1785). An Account of the Foxglove and some of its Medical Uses With Practical Remarks on Dropsy and Other Diseases. Archived from the original on 2017-09-08.
  47. ↑ Aronson JK (1985). An Account of the Foxglove and its Medical Uses 1785–1985 (1st ed.). London: Oxford University Press. pp. Chapters 5–7. ISBN   0192615017.
  48. ↑ Cushny AR (1925). "The Action and Uses in Medicine of Digitalis and its Allies". Nature (1st ed.). London: Longmans, Green and Co. 116 (2905): 8–9. Bibcode:1925Natur.116....8.. doi:10.1038/116008a0. hdl: 2027/uc1.b3846609 . S2CID   9025850.
  49. ↑ "digoxin". Wiktionary. Wikimedia. 16 January 2023. Retrieved 21 January 2023.
  50. 1 2 Smith S (1930). "LXXII.—Digoxin, a new digitalis glucoside". J. Chem. Soc. The Royal Society of Chemistry: 508–510. doi:10.1039/JR9300000508. Archived from the original on 2021-06-02. Retrieved 2020-10-22.
  51. ↑ "Victims' families set to confront killer". USA Today . 2006-01-01. Archived from the original on 2006-01-04.
  52. ↑ "Recalls, Market Withdrawals & Safety Alerts". Federal Drugs Administration. 2008-10-15. Archived from the original on 2008-05-02. Retrieved 2011-11-08.
  53. ↑ "Urgent Digitek Digoxin Recall". U.S. Recall News. 2008-04-28. Archived from the original on 2008-05-04. Retrieved 2009-07-25.
  54. ↑ "Patients Sue Icelandic Drugmaker Over Recalled Heart Drug". The Wall Street Journal . 2008-05-09. Archived from the original on 2009-04-13. Retrieved 2009-07-25.
  55. ↑ Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. (December 2008). "Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth". Proceedings of the National Academy of Sciences of the United States of America (re: glycosides). 105 (50): 19579–86. Bibcode:2008PNAS..10519579Z. doi: 10.1073/pnas.0809763105 . PMC   2604945 . PMID   19020076.
  56. ↑ Lopez-Lazaro M (March 2009). "Digoxin, HIF-1, and cancer". Proceedings of the National Academy of Sciences of the United States of America. 106 (9): E26, author reply E27. Bibcode:2009PNAS..106E..26L. doi: 10.1073/pnas.0813047106 . PMC   2651277 . PMID   19240208.
  57. ↑ Dal Canto MC (May 1989). "AIDS and the nervous system: current status and future perspectives". Human Pathology. 20 (5): 410–8. doi:10.1016/0046-8177(89)90004-x. PMID   2651280.
  58. ↑ "Digoxin: a medicine to treat heart problems". nhs.uk. 2021-09-15. Retrieved 2024-01-24.
  59. ↑ "Digoxin Tablets: Uses & Side Effects". Cleveland Clinic. Retrieved 2024-01-24.
  60. ↑ Yokoyama S, Sugimoto Y, Nakagawa C, Hosomi K, Takada M (November 2019). "Integrative analysis of clinical and bioinformatics databases to identify anticancer properties of digoxin". Scientific Reports. 9 (1): 16597. Bibcode:2019NatSR...916597Y. doi:10.1038/s41598-019-53392-y. PMC   6851125 . PMID   31719612.
  61. ↑ Kaapu KJ, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A (November 2016). "Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer". British Journal of Cancer. 115 (11): 1289–1295. doi:10.1038/bjc.2016.328. PMC   5129833 . PMID   27755533.
  62. ↑ Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Melbye M (June 2011). "Digoxin use and the risk of breast cancer in women". Journal of Clinical Oncology. 29 (16): 2165–70. doi: 10.1200/JCO.2010.32.8146 . PMID   21422417.
  63. ↑ Biggar RJ, Andersen EW, Kroman N, Wohlfahrt J, Melbye M (February 2013). "Breast cancer in women using digoxin: tumor characteristics and relapse risk". Breast Cancer Research. 15 (1): R13. doi: 10.1186/bcr3386 . PMC   3672748 . PMID   23421975.
  64. ↑ Ahern TP, Tamimi RM, Rosner BA, Hankinson SE (April 2014). "Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis". Breast Cancer Research and Treatment. 144 (2): 427–35. doi:10.1007/s10549-014-2886-x. PMC   4010120 . PMID   24573543.
  65. ↑ Deng K, Shen J, Wang W, Li M, Li H, Chen C, et al. (2019-01-02). "Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer". Cancer Biology & Therapy. 20 (1): 52–64. doi:10.1080/15384047.2018.1504723. PMC   6343689 . PMID   30183476.
  66. ↑ Chung MH, Wang YW, Chang YL, Huang SM, Lin WS (July 2017). "Risk of cancer in patients with heart failure who use digoxin: a 10-year follow-up study and cell-based verification". Oncotarget. 8 (27): 44203–44216. doi:10.18632/oncotarget.17410. PMC   5546474 . PMID   28496002.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.